Target raised raised on postive Q1 report... JMP securities raised its target price on Onyx Pharmaceuticals (ONXX) from $40 to $66 and maintained its outperform rating following stronger than expected Q1 results. The firm also called Onyx’s lead compound BAY43-9006 one of the most exciting compounds in the collective pipelines of biotech and pharma today. We have reviewed Onyx earlier this year when the Company reported that its lead compound had received Fast Track status at the FDA. (See Onyx Drug on Approval Fast Track.)
